Central Nervous System Disorders Therapeutics Market, By Disease Type, By Drug Class, By Distribution Channel, By Geography

Description

Central Nervous System Disorders Therapeutics Market is estimated to be valued at USD 139,307 Mn in 2026 and is expected to reach USD 228,639 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.4% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 139,307 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	7.40%	2033 Value Projection:	USD 228,639 Mn

Central nervous system (CNS) disorders are some of the most prevalent yet poorly treated illnesses. Achieving sufficient blood-brain barrier (BBB) penetration is one of the biggest challenges in the development of therapeutics for CNS disorders. For instance, according to an article published by National Center for Biotechnology Information, in January 2005, more than 98% of small molecular drugs and almost 100% of larger molecular drugs are ineffective in treating CNS diseases considering that BBB strictly limits the delivery of therapeutic agents to their target site in the CNS. BBB helps to keep homeostasis in the cerebral microenvironment by controlling exchanges of substances between the CNS and the blood and serves an important function in preventing macromolecules, infectious substances, and potential neurotoxins from entering the brain. CNS disorders are rising due to factors such as aging, stress, and, lifestyle changes.

A limited understanding of the pathophysiology underlies that most of the psychiatric disorders such as schizophrenia, major depressive disorder, or bipolar disorder are only effective in a limited proportion of the patients. Some of the CNS disorders include neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease along with various infectious diseases, psychiatric disorders, mental disorders, trauma, mood disorders, and others.

Market Dynamics

The key players are focusing on various growth strategies such as collaborations and agreements which is expected to drive the market growth during the forecast period. For instance, in July 2021, Eli Lilly and Company, an American pharmaceutical company and Banner Alzheimer's Institute announced a strategic research collaboration as part of the planned Phase 3, randomized, placebo-controlled study evaluating donanemab, a biological drug in trial to treat early symptoms of Alzheimer's disease in participants at risk for cognitive and functional decline related to Alzheimer's disease (TRAILBLAZER-ALZ 3). TRAILBLAZER-ALZ 3 will evaluate whether treatment with donanemab can slow the clinical progression of Alzheimer's disease in trial participants.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global central nervous system disorders therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Biogen Inc., Pfizer Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, AstraZeneca Plc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, AbbVie Inc., Glaxosmithkline plc., Otsuka Pharmaceutical Co., Ltd., Dr. Reddy's Laboratories Ltd., Cipla Inc., Lupin Ltd, and Glenmark Pharmaceuticals
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global central nervous system disorders therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global central nervous system disorders therapeutics market

Market Segmentation

By Disease Type Insights (Revenue, USD Mn, 2021 - 2033)
Neurodegenerative Disorders
- Alzheimer's Disease
- Parkinson's Disease
- Multiple Sclerosis
- Others
Infectious Diseases
Psychiatric Disorders
Anxiety Disorders
Trauma
Mood Disorders
Others
By Drug Class Insights (Revenue, USD Mn, 2021 - 2033)
Analgesics
Anti-cholinergic Agents
Anticonvulsants
Sedatives and Hypnotics
Antidepressants
Antipsychotics
Others
By Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region Insights (Revenue, USD Mn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- North Africa
- Central Africa
- South Africa
Key Players
Biogen Inc.
Pfizer Inc.
Eli Lilly and Company
Merck & Co., Inc.
Novartis AG
AstraZeneca Plc.
Teva Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
AbbVie Inc.
Glaxosmithkline plc.
Otsuka Pharmaceutical Co., Ltd.
Reddy's Laboratories Ltd.
Cipla Inc.
Lupin Ltd
Glenmark Pharmaceuticals

Product Code: CMI4544

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Disease Type
- Market Snapshot, By Drug Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunity
Impact Analysis
PEST Analysis
Regulatory Scenario
Market Trends
Key Developments
Pipeline Analysis
Regulatory Scenario
Epidemiology
Prescription Pattern and Prescribing Behavior

4. Global Central Nervous System Disorders Therapeutics Market, By Disease Type, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Neurodegenerative Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
  - Alzheimer's Disease
  - Parkinson's Disease
  - Multiple Sclerosis
  - Others
Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Psychiatric Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Anxiety Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Trauma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Mood Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

5. Global Central Nervous System Disorders Therapeutics Market, By Drug Class, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Analgesics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Anti-cholinergic Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Anticonvulsants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Sedatives and Hypnotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

6. Global Central Nervous System Disorders Therapeutics Market, By Distribution Channel, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

7. Global Central Nervous System Disorders Therapeutics Market, By Region, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - U.K.
  - Germany
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Region/Country, 2021 - 2033, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Heat Map Analysis
Market Share Analysis
Company Profile
- Biogen Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Eli Lilly and Company
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Merck & Co., Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Novartis AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- AstraZeneca Plc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Teva Pharmaceutical Industries Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Takeda Pharmaceutical Company Limited
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- AbbVie Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Glaxosmithkline plc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Otsuka Pharmaceutical Co., Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Reddy's Laboratories Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Cipla Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Lupin Ltd
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Glenmark Pharmaceuticals
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Analyst Views

9. Section

Research Methodology
About us